BioAegis Therapeutics, founded with a mission to combat inflammatory diseases, focuses on developing biomarker-directed treatments that restore depleted levels of plasma gelsolin, a natural human protein. This protein plays a crucial role in preventing the spread of inflammation, potentially averting multiple organ dysfunction syndrome. The company targets the healthcare industry, aiming to provide innovative solutions for conditions related to inflammation and infection.
Notable achievements include securing a $20 million BARDA DRIVe contract in October 2023 to advance treatments for Acute Respiratory Distress Syndrome (ARDS). BioAegis Therapeutics has made significant strides in clinical stages, leveraging its unique approach to harness innate immunity. The company's impactful work in restoring human protein levels has positioned it as a promising player in the field of inflammatory disease therapeutics.
